To what extent are the antimalarial markets in African countries ready for a transition to triple artemisinin-based combination therapies?
<h4>Introduction</h4>Triple artemisinin-based combination therapies (TACTs) are being developed as a response to artemisinin and partner drug resistance in the treatment of falciparum malaria in Southeast Asia. In African countries, where current artemisinin-based combination therapies (...
Guardado en:
Autores principales: | Freek de Haan, Oladimeji Akeem Bolarinwa, Rosemonde Guissou, Fatoumata Tou, Paulina Tindana, Wouter P C Boon, Ellen H M Moors, Phaik Yeong Cheah, Mehul Dhorda, Arjen M Dondorp, Jean Bosco Ouedraogo, Olugbenga A Mokuolu, Chanaki Amaratunga |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/0b7960eec00543d4ad1eae88bff71480 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
High-level production of amorpha-4,11-diene, a precursor of the antimalarial agent artemisinin, in Escherichia coli.
por: Hiroko Tsuruta, et al.
Publicado: (2009) -
Assessing antimalarial efficacy in a time of change to artemisinin-based combination therapies: the role of Médecins Sans Frontières.
por: Jean-Paul Guthmann, et al.
Publicado: (2008) -
A tetraoxane-based antimalarial drug candidate that overcomes PfK13-C580Y dependent artemisinin resistance
por: Paul M. O’Neill, et al.
Publicado: (2017) -
Correction: Corrigendum: Artemisinin-resistant Plasmodium falciparum clinical isolates can infect diverse mosquito vectors of Southeast Asia and Africa
por: Brandyce St. Laurent, et al.
Publicado: (2016) -
The origins of malaria artemisinin resistance defined by a genetic and transcriptomic background
por: Lei Zhu, et al.
Publicado: (2018)